Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artivion, Inc. Common Stock (NY:AORT)

22.93 +0.70 (+3.15%)
Official Closing Price Updated: 4:10 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
Artivion Inc (NYSE:AORT) Catches the GARP Eye With Affordable Growth Screen ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call
Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitabi... 
Via StockStory
Topics Earnings
News headline image
Artivion Q1 Earnings Call Highlights ↗
Artivion (NYSE:AORT) executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily... 
Via MarketBeat
Topics Earnings
News headline image
Why Artivion (AORT) Stock Is Falling Today
What Happened? Shares of medical device company Artivion (NYSE:AORT) fell 26.8% in the afternoon session after it reported first-quarter results that missed ... 
Via StockStory
Topics Earnings
Artivion Inc (NYSE:AORT) Stock Slides After Q1 Revenue Miss Despite Earnings Beat ↗
Via Chartmill
Artivion Inc (NYSE:AORT) Shares Drop on Q4 Revenue Miss Despite Earnings Beat ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
News headline image
AORT Q1 Deep Dive: Guidance Reset and Product Launches Shape 2026 Outlook
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o... 
Via StockStory
Topics Economy
News headline image
Artivion (AORT) Q1 2026 Earnings Transcript ↗
Artivion (AORT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Artivion’s (NYSE:AORT) Q1 CY2026 Earnings Results: Revenue In Line With Expectations
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the o... 
Via StockStory
News headline image
What To Expect From Artivion’s (AORT) Q1 Earnings
Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after market close. Here’s what you need to know. Artivion missed analys... 
Via StockStory
News headline image
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
Over the last six months, Artivion’s shares have sunk to $37.03, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 3.9% gain. This was... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Stock Under $50 to Own for Decades and 2 We Avoid
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline... 
Via StockStory
Topics ETFs
News headline image
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ... 
Via StockStory
News headline image
Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion
Check out the companies making headlines yesterday: Levi's (NYSE:LEVI): Denim clothing company Levi's (NYSE:LEVI) rose by 2.8% on Monday after investor optim... 
Via StockStory
News headline image
Why Artivion (AORT) Stock Is Down Today
What Happened? Shares of medical device company Artivion (NYSE:AORT) fell 2.1% in the afternoon session after a proposed 2027 federal budget revealed signifi... 
Via StockStory
Topics Artificial Intelligence Government Stocks
News headline image
1 Healthcare Stock on Our Watchlist and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t... 
Via StockStory
News headline image
Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
3 of Wall Street’s Favorite Stocks We Steer Clear Of
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea... 
Via StockStory
Topics Economy
News headline image
5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call
Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand... 
Via StockStory
Topics Earnings
News headline image
Artivion (AORT) Stock Trades Down, Here Is Why
Shares of medical device company Artivion (NYSE:AORT) fell 5.8% in the morning session after the company reported mixed fourth-quarter 2025 financial results, with revenues falling short of analyst... 
Via StockStory
News headline image
AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline
Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue... 
Via StockStory
News headline image
Artivion (AORT) Q4 2025 Earnings Call Transcript ↗
Artivion (AORT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
Medical device company Artivion (NYSE:AORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year... 
Via StockStory
News headline image
What To Expect From Artivion’s (AORT) Q4 Earnings
Medical device company Artivion (NYSE:AORT) will be reporting results this Thursday afternoon. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
2 Stocks Under $50 to Research Further and 1 We Avoid
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
1 Profitable Stock with Exciting Potential and 2 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.